Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest

Posted by Brenda Bartman on Sep 2nd, 2026

Actuate Therapeutics, Inc. (NASDAQ:ACTU – Get Free Report) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 695,971 shares, a growth of 54.6% from the July 30th total of 450,180 shares. Currently, 6.9% of the shares of the stock are short sold. Based on an average trading volume of 193,080 shares, the days-to-cover ratio is presently 3.6 days.

Analyst Ratings Changes

ACTU has been the subject of a number of recent research reports. Wall Street Zen cut shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Wednesday, June 24th. HC Wainwright reissued a “buy” rating on shares of Actuate Therapeutics in a research report on Tuesday, August 18th. Finally, Rodman & Renshaw assumed coverage on shares of Actuate Therapeutics in a research report on Thursday, July 30th. They issued a “buy” rating and a $6.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.50.

View Our Latest Stock Report on Actuate Therapeutics

Hedge Funds Weigh In On Actuate Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Voss Capital LP raised its holdings in shares of Actuate Therapeutics by 45.0% during the 4th quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock valued at $7,956,000 after purchasing an additional 403,722 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new stake in Actuate Therapeutics in the second quarter worth $157,000. Palogic Value Management L.P. acquired a new position in Actuate Therapeutics during the second quarter worth $153,000. BlackRock Inc. acquired a new position in Actuate Therapeutics during the second quarter worth $138,000. Finally, Geode Capital Management LLC raised its holdings in Actuate Therapeutics by 252.5% during the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after buying an additional 84,561 shares in the last quarter.

Actuate Therapeutics Stock Up 1.3%

ACTU stock opened at $1.54 on Wednesday. The company has a 50-day simple moving average of $1.34 and a 200 day simple moving average of $2.19. The company has a market capitalization of $36.98 million, a P/E ratio of -1.77 and a beta of 0.94. Actuate Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $9.22.

Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Equities analysts anticipate that Actuate Therapeutics will post -0.75 EPS for the current year.

About Actuate Therapeutics

(Get Free Report)

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.